Shares of Pandion Therapeutics soared more than 131 percent in trading after pharma giant Merck announced the acquisition of the autoimmune-focused company for up to $1.85 billion.
Merck exploded into the COVID-19 battle with three significant deals and collaborations.
Repertoire Immune Medicines officially launched following the merger of two complementary Flagship Pioneering companies, Torque Therapeutics and Cogen Immune Medicines. The new company is focused on tapping into the powers of the immune system to address numerous diseases.
PureTech Health signed a research collaboration deal with Germany’s Boehringer Ingelheim to develop novel product candidates using the Boston-based and London-listed company’s proprietary lymphatic targeting technology for immune modulation.
